Human immunodeficiency virus-associated thrombotic microangiopathies: Clinical characteristics and outcome according to ADAMTS13 activity

Scandinavian Journal of Immunology

Volumn 68, Issue 3, 2008, Pages 337-344

  Malak, S ^b   Wolf, M ^a   Millot, G A ^c   Mariotte, E ^a   Veyradier, A ^a   Meynard, J L ^b   Korach, J M ^d   Malot, S ^b   Bussel, A ^e   Azoulay, E ^a   Boulanger, E ^f   Galicier, L ^f   Devaux, E ^g   Eschwege V ^a   Gallien, S ^a   Adrie, C ^h   Schlemmer, B ^a   Rondeau, E ⁱ   Coppo, P ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c INSTITUT CURIE   (France)

^d Centre Hospitalier de Châlons en Champagne

^e Hôpital Saint Antoine ^*  (France)

^f SAINT LOUIS HOSPITAL   (France)

^g Centre Hospitalier Regional   (France)

^h DELAFONTAINE HOSPITAL   (France)

ⁱ HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FOLIC ACID; STEROID; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGED; AIDS RELATED COMPLEX; ARTICLE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS ASSOCIATED THROMBOTIC MICROANGIOPATHY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SPLENECTOMY; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADAM PROTEINS; ADULT; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; DEATH; FEMALE; FRANCE; HIV; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; VON WILLEBRAND FACTOR;

EID: 48749113224     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02143.x     Document Type: Article

References (50)

1. Furlan M, Robles R, Galbusera M et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998 339: 1578 84.
2. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998 339: 1585 94.
3. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002 100: 710 3.
4. Vesely SK, George JN, Lammle B et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003 102: 60 8.
5. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005 106: 11 7.
6. Levy GG, Nichols WC, Lian EC et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001 413: 488 94.
7. Scheiflinger F, Knobl P, Trattner B et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003 102: 3241 3.
8. Shelat SG, Smith P, Ai J, Zheng XL. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 2006 4: 1707 17.
9. Ferrari S, Scheiflinger F, Rieger M et al. Prognostic value of anti-ADAMTS13 antibodies features (Ig isotype, titer and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with an undetectable ADAMTS13 activity. Blood 2007 109: 2815 22.
10. Coppo P, Bengoufa D, Veyradier A et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004 83: 233 44.
11. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998 128: 541 4.
12. Bennett CL, Connors JM, Carwile JM et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000 342: 1773 7.
13. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001 98: 1765 72.
14. Gervasoni C, Ridolfo AL, Vaccarezza M et al. Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis 2002 35: 1534 40.
15. Becker S, Fusco G, Fusco J et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis 2004 39 (Suppl. 5 S267 75.
16. Sutor GC, Schmidt RE, Albrecht H. Thrombotic microangiopathies and HIV infection: report of two typical cases, features of HUS and TTP, and review of the literature. Infection 1999 27: 12 5.
17. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997 76: 369 80.
18. Gadallah MF, el-Shahawy MA, Campese VM, Todd JR, King JW. Disparate prognosis of thrombotic microangiopathy in HIV-infected patients with and without AIDS. Am J Nephrol 1996 16: 446 50.
19. Coppo P, Wolf M, Veyradier A et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2006 132: 66 74.
20. Coppo P, Bussel A, Charrier S et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 2003 82: 27 38.
21. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2006
22. Moses A, Nelson J, Bagby GC Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 1998 91: 1479 95.
23. Levine AM, Scadden DT, Zaia JA, Krishnan A. Hematologic aspects of HIV/AIDS. Hematology Am Soc Hematol Educ Program 2001 00: 463 78.
24. Gunther K, Garizio D, Nesara P. ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura. Transfusion 2007 47: 1710 6.
25. Platanias LC, Paiusco D, Bernstein S, Murali MR. Thrombotic thrombocytopenic purpura as the first manifestation of human immunodeficiency virus infection. Am J Med 1989 87: 699 700.
26. Rarick MU, Espina B, Mocharnuk R, Trilling Y, Levine AM. Thrombotic thrombocytopenic purpura in patients with human immunodeficiency virus infection: a report of three cases and review of the literature. Am J Hematol 1992 40: 103 9.
27. Sahud MA, Claster S, Liu L, Ero M, Harris K, Furlan M. von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. Br J Haematol 2002 116: 909 11.
28. Novitzky N, Thomson J, Abrahams L, du Toit C, McDonald A. Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy. Br J Haematol 2005 128: 373 9.
29. Ahmed S, Siddiqui RK, Siddiqui AK, Zaidi SA, Cervia J. HIV associated thrombotic microangiopathy. Postgrad Med J 2002 78: 520 5.
30. Badesha PS, Saklayen MG. Hemolytic uremic syndrome as a presenting form of HIV infection. Nephron 1996 72: 472 5.
31. de Man AM, Smulders YM, Roozendaal KJ, Frissen PH. HIV-related thrombotic thrombocytopenic purpura: report of 2 cases and a review of the literature. Neth J Med 1997 51: 103 9.
32. Ninin E, Merrien D, Hamidou M, Testa A, Milpied B, Raffi F. Thrombotic microangiopathies in HIV infection: 4 cases. Rev Med Interne 1996 17: 238 42.
33. Hymes KB, Karpatkin S. Human immunodeficiency virus infection and thrombotic microangiopathy. Semin Hematol 1997 34: 117 25.
34. Tostivint I, Mougenot B, Flahault A et al. Adult haemolytic and uraemic syndrome: causes and prognostic factors in the last decade. Nephrol Dial Transplant 2002 17: 1228 34.
35. Tamkus D, Jajeh A, Osafo D, Hadad L, Bhanot B, Yogore MG III. Thrombotic microangiopathy syndrome as an AIDS-defining illness: the experience of J. Stroger Hospital of Cook County. Clin Adv Hematol Oncol 2006 4: 145 9.
36. Thompson CE, Damon LE, Ries CA, Linker CA. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 1992 80: 1890 5.
37. Veenstra J, van der Lelie J, Mulder JW, Reiss P. Low-grade thrombotic thrombocytopenic purpura associated with HIV-1 infection. Br J Haematol 1993 83: 346 7.
38. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium 2000 7: 223 42.
39. Aukrust P, Bjornsen S, Lunden B et al. Persistently elevated levels of von Willebrand factor antigen in HIV infection. Downregulation during highly active antiretroviral therapy. Thromb Haemost 2000 84: 183 7.
40. del Arco A, Martinez MA, Pena JM et al. Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus infection: demonstration of p24 antigen in endothelial cells. Clin Infect Dis 1993 17: 360 3.
41. Hofman FM, Wright AD, Dohadwala MM, Wong-Staal F, Walker SM. Exogenous tat protein activates human endothelial cells. Blood 1993 82: 2774 80.
42. Park IW, Ullrich CK, Schoenberger E, Ganju RK, Groopman JE. HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J Immunol 2001 167: 2766 71.
43. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine (Baltimore) 1981 60: 413 28.
44. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 2003 127: 834 9.
45. Laurence J, Mitra D, Steiner M, Staiano-Coico L, Jaffe E. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood 1996 87: 3245 54.
46. Gunther K, Dhlamini B. D-dimer levels are markedly raised in HIV-related thrombotic thrombocytopenic purpura. AIDS 2007 21: 1063 4.
47. Salem G, Terebelo H, Raman S. Human immunodeficiency virus associated with thrombotic thrombocytopenic purpura: successful treatment with zidovudine. South Med J 1991 84: 493 5.
48. Gruszecki AC, Wehrli G, Ragland BD et al. Management of a patient with HIV infection-induced anemia and thrombocytopenia who presented with thrombotic thrombocytopenic purpura. Am J Hematol 2002 69: 228 31.
49. Miller RF, Scully M, Cohen H et al. Thrombotic thrombocytopaenic purpura in HIV-infected patients. Int J STD AIDS 2005 16: 538 42.
50. Aboulafia DM, Bundow D, Waide S, Bennet C, Kerr D. Initial observations on the efficacy of highly active antiretroviral therapy in the treatment of HIV-associated autoimmune thrombocytopenia. Am J Med Sci 2000 320: 117 23.